NEW YORK – Cancer detection firm Naveris is hoping for continued adoption of its assay for HPV-associated head and neck cancer recurrence this year as it explores additional use cases for its technology with multiple academic groups.
Despite launching the assay, called NavDx, shortly before the beginning of the coronavirus pandemic, the firm has seen significant growth, CEO Piyush Gupta said this week, with about 90 medical centers and over 130 physicians now using the test to surveil their patients for recurrence after initial surgery and other early treatments.